Jensen Investment Management Inc. Makes New $3.66 Million Investment in Hologic, Inc. (NASDAQ:HOLX)

Jensen Investment Management Inc. purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,760 shares of the medical equipment provider's stock, valued at approximately $3,659,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. State Street Corp increased its position in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock worth $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC increased its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Victory Capital Management Inc. raised its position in Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock valued at $354,506,000 after purchasing an additional 24,358 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock worth $208,051,000 after buying an additional 18,774 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock valued at $200,952,000 after buying an additional 195,285 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms recently commented on HOLX. Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target on the stock. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They set a "peer perform" rating on the stock. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Stock Performance

HOLX stock traded down $0.46 during trading on Thursday, hitting $61.01. 3,116,062 shares of the company's stock traded hands, compared to its average volume of 1,722,400. The stock has a market capitalization of $13.69 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The stock has a fifty day moving average price of $66.50 and a two-hundred day moving average price of $74.28. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.